What is Pristiq®?
Pristiq® (desvenlafaxine) belongs to the new generation class of serotonin-norepinephrine reuptake inhibitors (SNRIs).1,2 Pristiq® works by regulating the levels of serotonin and norepinephrine in the brain, thereby improving symptoms of emotional distress.3
Relieve emotional distress
Regain the life you deserve3
The benefits of Pristiq®
Significantly improves depressive symptoms as early as Week 14
Study showed that compared with placebo, treatment with Pristiq® resulted in significant improvements in depressive symptoms as early as Week 1.
Significantly improves functional impairment5
Study showed that compared with placebo, Pristiq® offers significant improvement in patients’ social, family, and work-life functioning within eight weeks.
High chance of remission6,7
Remission rate of emotional distress after receiving Pristiq® is higher than placebo. Serotonin–norepinephrine reuptake inhibitor (SNRIs), including Pristiq® is found to provide better remission rate than selective serotonin reuptake inhibitor (SSRIs).
Less likely to cause side effects8
A large comprehensive study including nine clinical trials showed that after taking Pristiq®, the discontinuation rate due to side effect is similar to placebo.
How do I take Pristiq®?9
- Pristiq® is an oral drug, can be taken with or without food
- The recommended dose for Pristiq® is 50mg once daily
- Tablets must be swallowed whole with fluid and not divided, crushed, chewed and dissolved
- Avoid alcohol consumption while taking Pristiq®
The safety of Pristiq®
The most common side effects with Pristiq® include nausea, dizziness, insomnia, constipation, fatigue, anxiety, and decreased appetite.7 Side effects, if they occur, usually emerge in the first week after taking Pristiq®, and are mostly mild in severity, transient in nature, and often subside.7,10 Studies with Pristiq® 50mg have shown that the rate of discontinuation due to side effects was 4.1%, similar to placebo, at 3.9%.8
Mental Health Assessment
Know More AboutMy Mental Health
References
- 1. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th edition, Cambridge University Press, 2013.
- 2. Kennedy SH, et al. Can J Psychiatry. 2016;61(9):540–560.
- 3. Thase ME, et al. CNS Spectr. 2009;14(3):144–154.
- 4. Katzman MA, et al. J Clin Psychopharmacol. 2017;37:555–561.
- 5. Soares CN, et al. CNS Spectr. 2019;24(3):322–332.
- 6. Machodo M, et al. J Clin Pharm Ther. 2010;35:177–188.
- 7. Boyer P, et al. Int Clin Psychopharmacol. 2008;23:243–253.
- 8. Clayton AH, et al. CNS Spectr. 2009;14(4):183–195.
- 9. Pristiq® (desvenlafaxine) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version March 2022.
- 10. Liebowitz MR & Tourian KA. Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09r00845.
PP-PRQ-HKG-0385 JUN 2023